Icecure Medical Ltd. 近日宣布，Sio 已正式向美国国家综合癌症网络（NCCN）提交请愿，恳请其将冷冻消融技术纳入乳腺癌治疗指南。此项动议的关键依据，正是 Icecure 旗下 Prosense® 系统已获得美国食品药品监督管理局（FDA）的上市许可。此举旨在推动这一微创疗法在乳腺癌治疗领域的更广泛应用。
Icecure Medical Ltd. 近日宣布，Sio 已正式向美国国家综合癌症网络（NCCN）提交请愿，恳请其将冷冻消融技术纳入乳腺癌治疗指南。此项动议的关键依据，正是 Icecure 旗下 Prosense® 系统已获得美国食品药品监督管理局（FDA）的上市许可。此举旨在推动这一微创疗法在乳腺癌治疗领域的更广泛应用。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.